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Introduction: The safety and efficacy of recombinant human soluble thrombomodulin (rhTM) have been
demonstrated, with promising evidence suggestive of efficacy for patients with severe sepsis involving
coagulopathy in a phase IIb randomized controlled trial. However, the benefit profiles of rhTM have not been
elucidated. The purpose of this study was to explore whether patients with greater disease severity, determined
according to the Acute Physiology and Chronic Health Evaluation (APACHE) II and Sequential Organ Failure
Assessment (SOFA) scores, would experience treatment benefit from rhTM administration.
Methods: This was a post hoc, subgroup analysis of a multicenter retrospective cohort study conducted in three
Japanese tertiary referral hospitals. Patients with sepsis-induced disseminated intravascular coagulation (DIC) who
required ventilator management were included. We stratified patients into several strata according to disease
severity, determined by APACHE II and SOFA scores, using classification and regression trees for survival data.
Intervention effects, expressed as hazard ratios (HR), were analyzed using Cox regression analysis adjusted for a
propensity model to detect subgroup heterogeneity of the effects of rhTM on in-hospital mortality.
Results: Participants were 162 patients with sepsis-induced DIC; 68 of these patients received rhTM and 94 did not.
After adjusting for imbalances, rhTM administration was significantly associated with reduced mortality in high-risk
patients (APACHE II: 24 to 29; HR: 0.281; 95% confidence interval (CI): 0.093 to 0.850; P = 0.025). A similar nonsignificant
tendency was observed in the very high-risk subset (APACHE II: ≥30; HR: 0.529; 95% CI: 0.202 to 1.387; P = 0.195) but
was not evident in the moderate-risk subset of patients (APACHE II: <24; HR: 0.814; 95% CI: 0.351 to 1.884; P = 0.630). A
similar tendency was observed in analysis of SOFA scores (moderate-risk subset (SOFA: <11), P = 0.368; high-risk subset
(SOFA: ≥11), P = 0.042).
Conclusions: Survival benefit was observed with rhTM treatment in sepsis-induced DIC and high risk of death
according to baseline APACHE II and SOFA scores.* Correspondence: k.yamakawa0911@gmail.com
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Crosstalk between the coagulation system and inflam-
matory reactions during sepsis causes organ damage
followed by multiple organ dysfunction syndrome or
death [1-3]. Anticoagulant therapies are therefore expec-
ted to be beneficial in the treatment of severe sepsis.
Numerous large clinical trials using anticoagulant agents,
such as recombinant human activated protein C (rhAPC)
[4], tissue factor pathway inhibitor [5], and antithrombin
(AT) [6], have been conducted over the past 10 years to
evaluate mortality benefit for patients with severe sepsis.
While these trials failed to reduce 28-day mortality for all
patients with severe sepsis, some subgroup analyses have
been conducted to identify patient groups who could
benefit from anticoagulant therapy. Consequently, anti-
coagulant therapies might only be effective for patients
with severe sepsis involving disseminated intravascular co-
agulation (DIC) and high risk of death [7].
Thrombomodulin is a thrombin receptor present on
the endothelial cell surface and plays an important role
in the regulation of intravascular coagulation [8]. Recom-
binant human soluble thrombomodulin (rhTM) is widely
used in the treatment of DIC in Japan. In a previous study,
we demonstrated that rhTM may have a significant benefi-
cial effect on mortality in mechanically ventilated adult
patients with sepsis-induced DIC [9]. Moreover, the safety
and efficacy of rhTM was demonstrated, with promising
evidence of efficacy, in a phase IIb randomized controlled
trial and is currently under evaluation in a phase III trial
[10]. While the subgroup analysis of the phase IIb trial
suggested that patients with respiratory or cardiac dys-
function and coagulopathy characterized by prothrombin
time–International Normalized Ratios >1.4 at baseline
could benefit from rhTM administration, the benefit pro-
files have not been thoroughly elucidated.
This study aimed to analyze the efficacy of rhTM treat-
ment in sepsis-induced DIC according to disease severity
defined by Acute Physiology and Chronic Health Evaluation




This investigation was a post hoc subgroup analysis of a
multicenter retrospective cohort study conducted in
three Japanese tertiary referral hospitals between January
2006 and June 2011 [9]. Inclusion criteria were as fol-
lows: infection known or suspected on the basis of
clinical data at study entry, two or more signs of sys-
temic inflammation with the presence of sepsis-induced
organ dysfunction, hematologic dysfunction (platelet
count <80,000/mm3), and the need for mechanical ven-
tilation to stabilize the patient’s general condition. All
patients fulfilled the criteria for the Japanese Associationfor Acute Medicine (JAAM) DIC scoring system [11]. The
exclusion criteria were as follows: fatal or life-threatening
bleeding (intracranial, gastrointestinal, or pulmonary);
history of cerebrovascular disorder (cerebral bleeding or
infarction) within 1 year; age ≤15 years; history of hyper-
sensitivity to protein preparations or unfractionated hep-
arin; pregnancy or breastfeeding; and fulminant hepatitis,
decompensated liver cirrhosis, or other serious liver
disorder.
Participants were 162 patients with sepsis-induced
DIC who were categorized into one of two groups: the
rhTM group, comprising 68 patients who received rhTM;
or the control group, comprising 94 patients who received
no rhTM. In our retrospective study, there was no prede-
fined protocol regarding definite indications for rhTM
treatment. For patients with severe sepsis fulfilling the
criteria for DIC, rhTM was used at the discretion of the
attending physician. In the rhTM group, rhTM was mainly
administered intravenously at a dose of 0.06 mg/kg/day,
and infusion continued for 6 days. All patients were
treated according to the strategy described in the Surviv-
ing Sepsis Campaign Guidelines [12]. We did not adminis-
ter rhAPC to either group, because it had not been
approved for the treatment of severe sepsis in Japan.
This study followed the principles of the Declaration
of Helsinki. The study was approved by the Institutional
Review Board of the Osaka General Medical Center, and
the board waived the need for informed consent for retro-
spective studies such as this.
Data collection
Baseline characteristics, including demographic informa-
tion and data concerning preexisting conditions, organ
function/failure, infection, and pertinent medications, were
recorded. The variables used to assess comparability be-
tween the two groups were age, sex, APACHE II score,
SOFA score, number of dysfunctional organs, infection
site, and positive blood culture rate.
The primary outcome measure was in-hospital mortality.
We also recorded complications including the occurrence
of intracranial hemorrhage, gastrointestinal hemorrhage,
respiratory tract hemorrhage, and minor transfusions.
Minor transfusion was defined as the administration of 4
units of red blood cells or more within two consecutive
days for up to 14 days.
Statistical analysis
The aim of this study was to identify a subset of patients
with high benefit profiles for rhTM treatment. Classifi-
cation and regression trees for survival data (survival
CART) were used to classify patients according to dis-
ease severity determined by APACHE II, SOFA, and
JAAM DIC scores. Survival CART analysis for APACHE
II scores revealed that the first split point at which to
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treatment was an APACHE II score of 30, and the
second split points were APACHE II scores of 24 for
all subsets of patients (Figure 1). The intervention ef-
fects of rhTM treatment were therefore estimated in
three subsets.
Owing to the retrospective nature of the study, there
were baseline imbalances between the two groups of
patients; therefore, an adjusted mortality analysis was
performed using propensity scores [13,14]. The propen-
sity score for receiving rhTM was calculated using multi-
variate logistic regression and included 15 independent
variables, as described in our previous report [9], com-
prising age, sex, illness severity (APACHE II score, SOFA
score, number of dysfunctional organs, and positive blood
culture), JAAM DIC score, respiratory dysfunction, time
from severe sepsis onset to study entry (defined according
to a 48-hour cutoff point), a past medical history of severe
conditions (diabetes mellitus and immunosuppressive the-
rapy), source of infection, and therapeutic interventions
(heparin administration, AT administration, or emer-
gency operations). The c statistic was 0.792. The Hosmer–
Lemeshow chi-square value was 9.585 (degrees of
freedom = 8), with a nonsignificant P value of 0.295,
which indicates that the model fit well.
Patients were stratified into quintiles according to pro-
pensity score. The overall effectiveness of treatment with
respect to mortality was assessed using the Cox regres-
sion model with defined strata. Exact method analyses
were performed to examine secondary outcomes involv-
ing bleeding complications.Figure 1 Control group stratification according to baseline
APACHE II scores using the classification and regression tree
method. APACHE, Acute Physiology and Chronic Health Evaluation.Descriptive statistics were calculated as medians (inter-
quartile range) or proportions, as appropriate. Univariate
differences between groups were assessed using the
Mann–Whitney U test, Kruskal–Wallis test, chi-square
test, or Fisher’s exact test. P <0.05 indicated statistical
significance. All statistical analyses were performed using
IBM SPSS Statistics version 22.0 for Windows (SPSS Inc.,
Chicago, IL, USA), SAS Statistical Software version 9.3 for
Windows (SAS Institute Inc., Cary, NC, USA), or an in-
house validated FORTRAN program.
Results
Baseline characteristics
During the study period, 162 consecutive patients ful-
filled the inclusion criteria. The rhTM group comprised
68 patients, and the control group comprised 94 pa-
tients. Baseline characteristics and therapeutic interven-
tions for the study population are presented in Table 1.
Baseline illness severity determined by APACHE II and
SOFA scores, numbers of dysfunctional organs, and
rates of positive blood culture were significantly higher
in the rhTM group relative to the control group. The
two groups did not differ significantly with respect to co-
agulation parameters including DIC scores, past medical
history of severe conditions, infection site, and therapeutic
intervention. The median duration of rhTM administra-
tion was 6.0 (interquartile range 4.0 to 6.0) days, and the
median dose of rhTM administration was 0.059 (0.043 to
0.065) mg/kg/day in the rhTM group.
Table 2 presents the baseline characteristics of three
subsets stratified according to APACHE II scores using
survival CART analysis. Patient characteristics, such as
age and sex, were similar between the three APACHE II
score subsets. Illness severity, as indicated by APACHE
II and SOFA scores, number of dysfunctional organs,
and International Society of Thrombosis and Hemostasis
(ISTH) DIC scores, showed a significant gradual increase
with rising APACHE II scores. Time from onset of se-
vere sepsis to study entry was significantly shorter in the
two high-risk subsets relative to the moderate-risk
subset.
Effect of treatment on mortality according to baseline
disease severity
The survival curves in the prediction model, according
to covariates of propensity scores for subsets determined
by baseline APACHE II scores, are shown for the rhTM
and control groups in Figure 2. Cox regression analysis
suggested that rhTM administration was significantly
associated with reduced mortality, but only in patients
in the high-risk subset (APACHE II score = 24 to 29;
adjusted hazard ratio = 0.281; 95% confidence interval =
0.093 to 0.850; P = 0.025). In addition, a similar but non-
significant tendency was observed in the very-high-risk
Table 1 Baseline characteristics of all patients with sepsis-induced DIC untreated or treated with rhTM
Overall (n = 162) rhTM group (n = 68) Control group (n = 94) P valuea
Patient characteristics
Age (years)b 69 (59 to 76) 69 (61 to 76) 70 (57 to 77) 0.953
Male sexb 93 (57%) 36 (53%) 57 (61%) 0.339
Illness severity
APACHE II scoreb 23 (19 to 29) 25 (21 to 32) 22 (18 to 27) 0.008
SOFA scoreb 11 (9 to 13) 12 (9 to 13) 11 (8 to 12) 0.029
Number of dysfunctional organsb 4 (3 to 5) 4 (3 to 5) 4 (3 to 5) 0.383
Positive blood cultureb 72 (44%) 41 (60%) 31 (33%) 0.001
Coagulation parameters
Platelet count (/mm3) 4.9 (2.7 to 6.5) 4.4 (2.6 to 6.4) 5.3 (2.8 to 6.6) 0.081
PT-INR 1.40 (1.23 to 1.70) 1.40 (1.20 to 1.67) 1.50 (1.30 to 1.78) 0.169
FDP (μg/ml) 22.3 (11.0 to 55.5) 24.6 (13.2 to 60.0) 20.3 (10.2 to 48.9) 0.380
Fibrinogen level (mg/dl) 350 (224 to 495) 357 (225 to 553) 328 (213 to 456) 0.231
JAAM DIC scoreb 6 (5 to 8) 6 (5 to 8) 6 (5 to 8) 0.555
ISTH DIC score 4 (3 to 5) 4 (4 to 5) 4 (3 to 5) 0.457
Organ failure
Respiratoryb 114 (70%) 54 (79%) 60 (64%) 0.037
Circulatory 134 (83%) 57 (84%) 77 (82%) 0.835
Kidney 86 (53%) 37 (54%) 49 (52%) 0.873
Metabolic 96 (59%) 40 (59%) 56 (60%) 1.000
Hematologic 162 (100%) 68 (100%) 94 (100%) 1.000
Time from severe sepsis onset to study entryb 0.689
Early (≤48 hours) 114 (70%) 49 (72%) 65 (69%)
Late (>48 hours) 48 (30%) 19 (28%) 29 (31%)
Co-morbidities
Diabetesb 32 (20%) 17 (25%) 15 (16%) 0.167
Hypertension 38 (24%) 18 (27%) 20 (21%) 0.458
Hemodialysis 9 (6%) 2 (3%) 7 (7%) 0.306
Immunosuppressionb 19 (12%) 11 (16%) 8 (9%) 0.146
Malignant disease 12 (7%) 5 (7%) 7 (7%) 1.000
Infection siteb 0.100c
Lung 32 (20%) 10 (15%) 22 (23%)
Abdomen 62 (38%) 23 (34%) 39 (42%)
Soft tissue 31 (19%) 13 (19%) 18 (19%)
Urinary tract 21 (13%) 14 (21%) 7 (7%)
Other/unknown 16 (10%) 8 (12%) 8 (9%)
Therapeutic interventions
Vasopressor 131 (81%) 57 (84%) 74 (79%) 0.429
Steroid 49 (30%) 16 (24%) 33 (35%) 0.123
Heparin/heparinoidb 18 (11%) 4 (6%) 14 (15%) 0.081
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Table 1 Baseline characteristics of all patients with sepsis-induced DIC untreated or treated with rhTM (Continued)
Antithrombinb 16 (10%) 9 (13%) 7 (7%) 0.288
Renal replacement therapy 48 (30%) 20 (29%) 28 (30%) 1.000
Emergency operationb 63 (39%) 20 (29%) 43 (46%) 0.050
APACHE, Acute Physiology and Chronic Health Evaluation; DIC, disseminated intravascular coagulation; FDP, fibrin/fibrinogen degradation products; ISTH,
International Society on Thrombosis and Hemostasis; JAAM, Japanese Association for Acute Medicine; PT-INR, prothrombin time–International Normalized Ratio;
rhTM, recombinant human soluble thrombomodulin; SOFA, Sequential Organ Failure Assessment. Data are expressed as group median (interquartile range) or
proportion (%). aP value for rhTM-treated patients versus untreated patients. bThe 15 variables used in propensity score calculation. cOnly one P value, for site of
infection, is shown because the test was performed as a chi-square test on a 2 × 5 crosstable.
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0.529; 95% confidence interval = 0.202 to 1.387; P = 0.195);
however, this was not evident in the moderate-risk subset
of patients (APACHE II score <24; hazard ratio = 0.814;
95% confidence interval = 0.351 to 1.884; P = 0.630).
A similar tendency was also observed in the analysis of
subsets based on a number of other clinical measures of
baseline disease severity (Figure 3). When the population
was separated into subsets according to SOFA scores,
the favorable rhTM treatment effect was only obser-
ved in the subset with SOFA scores ≥11. With respect
to DIC severity, the favorable rhTM treatment effect
was only observed in subsets with high DIC severity
(JAAM DIC score = 8). In contrast, similar mortality
rates were observed in ISTH overt DIC classes with
rhTM therapy.Table 2 Baseline characteristics of different subsets stratified
Moderate risk (n = 86)
Patient characteristics
Age (years) 67 (57 to 76)
Male sex 50 (58%)
Illness severity
APACHE II score 19 (16 to 21)
SOFA score 9 (7 to 11)
Number of dysfunctional organs 3 (2 to 4)
Positive blood culture 31 (36%)
JAAM DIC score 6 (5 to 8)
ISTH DIC score 4 (3 to 5)
Time from severe sepsis onset to study entry
Early (≤48 hours) 53 (62%)




Soft tissue 19 (22%)
Urinary tract 9 (11%)
Other/unknown 6 (7%)
APACHE, Acute Physiology and Chronic Health Evaluation; DIC, disseminated intrava
JAAM, Japanese Association for Acute Medicine; SOFA, Sequential Organ Failure Asses
(%). aP value between three subsets in the Kruskal–Wallis or chi-square test. bOnly one
chi-square test on a 3 × 5 crosstable.Adverse events
Bleeding complications in baseline APACHE II score sub-
sets are presented in Figure 4. Rates of minor transfusion
and gastrointestinal, respiratory tract, and intracranial
bleeding were similar in the treated and untreated groups.
However, analysis of bleeding complications was insuffi-
cient because of the small sample sizes of the subsets.
Discussion
The present study represents the first attempt to evalu-
ate the benefit profile of rhTM in sepsis-induced DIC.
The results of this study provide evidence that rhTM
improved mortality in a high-risk subset (APACHE II
score = 24 to 29) of patients with sepsis-induced DIC.
The current analysis also indicates that patients in the
moderate-risk subset (APACHE II score <24) may notby baseline APACHE II score
High risk (n = 41) Very high risk (n = 35) P valuea
69 (58 to 76) 72 (66 to 78) 0.171
26 (63%) 17 (49%) 0.419
27 (25 to 28) 33 (32 to 36) <0.001
12 (11 to 13) 13 (11 to 15) <0.001
4 (3 to 5) 5 (4 to 5) <0.001
23 (56%) 18 (51%) 0.067
6 (5 to 8) 8 (6 to 8) 0.092
4 (4 to 5) 5 (4 to 5) 0.018
0.035
33 (81%) 28 (80%)
8 (20%) 7 (20%)
0.457b
6 (15%) 9 (26%)
16 (39%) 11 (31%)
9 (22%) 3 (9%)
5 (12%) 7 (20%)
5 (12%) 5 (14%)
scular coagulation; ISTH, International Society on Thrombosis and Hemostasis;
sment. Data are expressed as group median (interquartile range) or proportions
P value, for site of infection, is shown because the test was performed as a
Figure 2 Adjusted estimated survival curves in subsets
stratified according to baseline APACHE II scores. (A) Moderate-
risk subset of patients (APACHE II score <24). (B) High-risk subset
(APACHE II score = 24 to 29). (C) Very high-risk subset (APACHE II
score ≥30). Solid line, patients in the rhTM group; dotted line,
patients in the control group. Administration of rhTM was only
associated with significantly reduced mortality in patients in the
high-risk subset (APACHE II score = 24 to 29; P = 0.025, Cox regression
analysis). APACHE, Acute Physiology and Chronic Health Evaluation;
rhTM, recombinant human soluble thrombomodulin.
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dencies, with respect to mortality benefit, have been
evaluated in analyses of other anticoagulant therapies.
The subgroup analysis of the Recombinant Human Acti-
vated Protein C Worldwide Evaluation in Severe Sepsis
trial suggested increasing absolute and relative risk reduc-
tion in rhAPC treatment with greater risk of death, using
higher APACHE II scores (≥25) and greater incidence oforgan failure [15]. In addition, AT treatment improved
mortality in patients with severe sepsis and a predicted
mortality of 30 to 60% in the KyberSept trial subgroup
analysis [7]. These previous analyses suggest that anti-
coagulant therapies may only be effective for patients
with severe sepsis involving a high risk of death.
Why are anticoagulant therapies for severe sepsis only
effective for patients with a high risk of death? Generally,
it is difficult to determine the survival benefit of a par-
ticular lifesaving therapy in a set of patients with a low
risk of mortality. This may be one of the reasons why
rhTM administration does not reduce the mortality risk
in patients who are not at high risk in the first place. On
the other hand, these results are congruent with recent
pathophysiological findings concerning the innate im-
mune response. Under certain circumstances, thrombosis
is considered to play a major physiological role, which is
specifically named immunothrombosis, in immune defense
[16]. However, aberrant or uncontrolled activation of
immunothrombosis is likely to constitute a key event in
the development of thrombotic disorders [2]. In patients
in the moderate-risk subset, rhTM could have inhibited
host-defensive thrombosis, which helps to capture and
ensnare pathogens circulating in the blood, and therefore
failed to improve mortality. In contrast, immunothrom-
bosis could have been aberrantly activated and proved
detrimental to the host in patients in the high-risk
and very-high-risk subsets, which may have improved
mortality.
Although several DIC criteria have been established
[11,17], whether one criterion performs better than
others in detecting patients who require anticoagulant
therapies has not been elucidated. In a double-blind ran-
domized controlled phase IIb study [10], mortality bene-
fit was not observed in patients with ISTH overt DIC. In
addition, in the current analysis there was no statistically
significant correlation between ISTH DIC scores and
mortality; however, mortality benefit was observed with
rhTM in DIC patients with JAAM DIC scores of 8.
Bleeding was the most significant adverse event associ-
ated with rhTM administration, as well as other anti-
coagulant agents. Indeed, there were more bleeding events
with activated protein C and AT relative to a placebo in
previous studies [6,18]. Rates of bleeding events were reas-
sessed with respect to illness severity based on APACHE
II scores, and there was no increase in bleeding-related
adverse events in illness of any severity. However, the
subsets were too small to allow observation of adverse
effects.
We acknowledge several limitations to our study, which
were mentioned in the original paper [9]. The study
was not a randomized controlled trial. The relatively
long time span of the study could have been associ-
ated with the introduction of therapeutic measures that
Figure 3 In-hospital mortality across subsets defined according to measures of baseline disease severity and infection characteristics.
APACHE, Acute Physiology and Chronic Health Evaluation; CI, confidence interval; DIC, disseminated intravascular coagulation; ISTH, International
Society of Thrombosis and Hemostasis; JAAM, Japanese Association for Acute Medicine; rhTM, recombinant human soluble thrombomodulin;
SOFA, Sequential Organ Failure Assessment.
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the study being retrospective, the treatment intervention
being examined was not standardized (for example, dose
and durations of rhTM administration), and the base-
line characteristics were different between the two groups.
In the present study, we developed a propensity score
approach to cope with the nonrandomization. TheFigure 4 Bleeding complications in subsets stratified according to ba
Health Evaluation; CI, confidence interval; rhTM, recombinant human solubcombination of these limitations might cause multiple
unmeasured variables to account for the outcome differ-
ences observed in this study. Also, as this study involved
subgroup analysis, we cannot deny the potential of ac-
cidental false positive results. Some interventions against
sepsis such as rhAPC failed to show a mortality benefit in
subsequent large randomized controlled trials [4], althoughseline APACHE II scores. APACHE, Acute Physiology and Chronic
le thrombomodulin.
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data of subgroup analysis in previous trials. The study
was also prone to false negative results due to inadequate
power with which to uncover treatment effect differences,
even in the presence of true treatment-effect modification.
Further multicenter prospective randomized trials are
required to evaluate efficacy and safety distinctly.
Conclusions
We observed a survival benefit with rhTM treatment in
sepsis-induced DIC patients with baseline APACHE II
scores ≥24 or SOFA scores ≥11. These findings sugges-
ted an increase in treatment benefit with greater risk of
death and indicated that application of rhTM treatment
may only be limited to sepsis patients with a high risk of
death in clinical settings.
Key messages
 We identified a subset of patients with high benefit
profiles for rhTM treatment by stratifying the study
sample according to APACHE II and SOFA scores,
using survival CART analysis.
 Survival benefit was only observed with rhTM
treatment for sepsis-induced DIC in a high-risk
subset of patients with APACHE II scores ≥24 or
SOFA scores ≥11.
 The results suggested that the survival benefit of
rhTM administration may only be experienced by
patients with sepsis-induced DIC involving a high
risk of death.
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